Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soldano Ferrone

Showing results (291-300 of 334) with videos related to

Pageof 34
Sort By:
Ebiomedicine|August 31, 2019
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheresDean Nehama, Natalia Di Ianni, Silvia Musio, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2014
CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNAFederica Riccardo, Selina Iussich, Lorella Maniscalco, et al.
Nature Communications|December 4, 2018
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumoursAurélie Durgeau, Yasemin Virk, Gwendoline Gros, et al.
Frontiers in Immunology|February 15, 2021
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, QatarBella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, et al.
The Oncologist|February 14, 2019
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive ChemoradiotherapyDevarati Mitra, Nora K Horick, Diane G Brackett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2019
Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA ProcessingTian Tian, Xiaobin Lv, Guokai Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
Genetic evolution of T-cell resistance in the course of melanoma progressionAntje Sucker, Fang Zhao, Birgit Real, et al.
Frontiers in Immunology|March 16, 2019
Iron and Ferritin Modulate MHC Class I Expression and NK Cell RecognitionRosa Sottile, Giorgia Federico, Cinzia Garofalo, et al.
Neoplasia (New York, N.Y.)|February 25, 2014
HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic markerGiuseppe Sconocchia, Serenella Eppenberger-Castori, Inti Zlobec, et al.
Pageof 34

Showing results (291-300 of 334) with videos related to

Sort By:
Pageof 34
Ebiomedicine|August 31, 2019
B7-H3-redirected chimeric antigen receptor T cells target glioblastoma and neurospheresDean Nehama, Natalia Di Ianni, Silvia Musio, et al.
Journal of Translational Medicine|January 7, 2021
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutationEster Simeone, Giosuè Scognamiglio, Mariaelena Capone, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2014
CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNAFederica Riccardo, Selina Iussich, Lorella Maniscalco, et al.
Nature Communications|December 4, 2018
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumoursAurélie Durgeau, Yasemin Virk, Gwendoline Gros, et al.
Frontiers in Immunology|February 15, 2021
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15<sup>th</sup>-16<sup>th</sup> February 2019, Doha, QatarBella Guerrouahen, Muhammad Elnaggar, Anjud Al-Mohannadi, et al.
The Oncologist|February 14, 2019
High IDO1 Expression Is Associated with Poor Outcome in Patients with Anal Cancer Treated with Definitive ChemoradiotherapyDevarati Mitra, Nora K Horick, Diane G Brackett, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 20, 2019
Long Noncoding RNA MPRL Promotes Mitochondrial Fission and Cisplatin Chemosensitivity via Disruption of Pre-miRNA ProcessingTian Tian, Xiaobin Lv, Guokai Pan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 9, 2014
Genetic evolution of T-cell resistance in the course of melanoma progressionAntje Sucker, Fang Zhao, Birgit Real, et al.
Frontiers in Immunology|March 16, 2019
Iron and Ferritin Modulate MHC Class I Expression and NK Cell RecognitionRosa Sottile, Giorgia Federico, Cinzia Garofalo, et al.
Neoplasia (New York, N.Y.)|February 25, 2014
HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic markerGiuseppe Sconocchia, Serenella Eppenberger-Castori, Inti Zlobec, et al.
Pageof 34